The primary objective of this study is to assess the effects of clopidogrel on the PK of K-877 in healthy adult subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
20
Unnamed facility
Cincinnati, Ohio, United States
Plasma exposure of K-877 by measuring Cmax when administered alone or with Clopidogrel
Time frame: Up to 72 hours after dosing
Plasma exposure of K-877 by measuring AUC when administered alone or with Clopidogrel
Time frame: Up to 72 hours after dosing
Evaluation of 20 participants with treatment emergent adverse events as assessed by the principle investigator
Subjects will be questioned in a general way by the investigator without specific symptoms suggested.
Time frame: Through study completion up to 17 days.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.